<SEC-DOCUMENT>0000950170-25-083676.txt : 20250609
<SEC-HEADER>0000950170-25-083676.hdr.sgml : 20250609
<ACCEPTANCE-DATETIME>20250609160054
ACCESSION NUMBER:		0000950170-25-083676
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		13
CONFORMED PERIOD OF REPORT:	20250604
ITEM INFORMATION:		Entry into a Material Definitive Agreement
ITEM INFORMATION:		Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
ITEM INFORMATION:		Submission of Matters to a Vote of Security Holders
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20250609
DATE AS OF CHANGE:		20250609

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			FIBROGEN INC
		CENTRAL INDEX KEY:			0000921299
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		ORGANIZATION NAME:           	03 Life Sciences
		EIN:				000000000
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-36740
		FILM NUMBER:		251033906

	BUSINESS ADDRESS:	
		STREET 1:		350 BAY STREET
		STREET 2:		SUITE 100 #6009
		CITY:			SAN FRANCISCO
		STATE:			CA
		ZIP:			94133
		BUSINESS PHONE:		415-978-1200

	MAIL ADDRESS:	
		STREET 1:		350 BAY STREET
		STREET 2:		SUITE 100 #6009
		CITY:			SAN FRANCISCO
		STATE:			CA
		ZIP:			94133
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>fgen-20250604.htm
<DESCRIPTION>8-K
<TEXT>
<XBRL>
<?xml version='1.0' encoding='ASCII'?>
<!-- DFIN New ActiveDisclosure (SM) Inline XBRL Document - http://www.dfinsolutions.com/ -->
<!-- Creation Date :2025-06-09T15:55:50.0666+00:00 -->
<!-- Copyright (c) 2025 Donnelley Financial Solutions, Inc. All Rights Reserved. -->
<html xmlns="http://www.w3.org/1999/xhtml" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:nonNumeric="http://www.xbrl.org/dtr/type/non-numeric" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:dei="http://xbrl.sec.gov/dei/2025" xmlns:fgen="http://www.fibrogen.com/20250604" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2022-02-16">
 <head>
  <title>8-K</title>
  <meta http-equiv="Content-Type" content="text/html"/>
 </head>
 <body style="padding:8px;margin:auto!important;z-index:0;-webkit-text-size-adjust:100%;position:relative;">
  <div style="display:none;"><ix:header><ix:hidden><ix:nonNumeric id="F_3b65e9a4-6154-4acb-9acf-0d8df1c457dc" name="dei:EntityCentralIndexKey" contextRef="C_635a69f0-1a0c-4eb4-9b96-ad916bfa62eb">0000921299</ix:nonNumeric><ix:nonNumeric id="F_a1797866-cf90-4367-b394-152099b6f327" name="dei:AmendmentFlag" contextRef="C_635a69f0-1a0c-4eb4-9b96-ad916bfa62eb">false</ix:nonNumeric></ix:hidden><ix:references><link:schemaRef xlink:type="simple" xlink:href="fgen-20250604.xsd"/></ix:references><ix:resources><xbrli:context id="C_635a69f0-1a0c-4eb4-9b96-ad916bfa62eb"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000921299</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2025-06-04</xbrli:startDate><xbrli:endDate>2025-06-04</xbrli:endDate></xbrli:period></xbrli:context></ix:resources></ix:header></div>
  <div style="z-index:2;min-height:0.5in;position:relative;"></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="border-top:2.25pt double #000000;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:5.75pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:18pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">UNITED STATES<br/>SECURITIES AND EXCHANGE COMMISSION<br/></span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">WASHINGTON, D.C. 20549</span></p><p style="margin-left:40%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;border-bottom:0.75pt solid #000000;margin-right:40%;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><h2 style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:18pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">FORM </span><span style="font-size:18pt;font-family:Times New Roman;"><ix:nonNumeric id="F_9036f13e-3e42-4021-840c-8b8e1f10e17e" contextRef="C_635a69f0-1a0c-4eb4-9b96-ad916bfa62eb" name="dei:DocumentType"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:18pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">8-K</span></ix:nonNumeric></span></h2><p style="margin-left:40%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;border-bottom:0.75pt solid #000000;margin-right:40%;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:9pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">CURRENT REPORT</span></p><p style="font-size:10pt;margin-top:9pt;font-family:Times New Roman;margin-bottom:6pt;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934</span></p>
   <table style="border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;">
    <tr style="visibility:collapse;">
     <td style="width:100%;box-sizing:content-box;"/>
    </tr>
    <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;text-align:left;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.398%;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Date of Report (Date of earliest event reported): </span><span><ix:nonNumeric id="F_1af18199-20b5-4f32-9d1c-c504d051d337" contextRef="C_635a69f0-1a0c-4eb4-9b96-ad916bfa62eb" name="dei:DocumentPeriodEndDate" format="ixt:date-monthname-day-year-en"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">June 04, 2025</span></ix:nonNumeric></span></p></td>
    </tr>
   </table><p style="margin-left:40%;font-size:10pt;margin-top:5pt;font-family:Times New Roman;margin-bottom:0;border-bottom:0.75pt solid #000000;margin-right:40%;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:5pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="font-size:24pt;font-family:Times New Roman;"><ix:nonNumeric id="F_4b57d9b7-11f0-4dd0-a7e7-cb2045866d9b" contextRef="C_635a69f0-1a0c-4eb4-9b96-ad916bfa62eb" name="dei:EntityRegistrantName"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:24pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">FIBROGEN, INC.</span></ix:nonNumeric></span></p><p style="font-size:10pt;margin-top:3pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:7.5pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(Exact name of Registrant as Specified in Its Charter)</span></p><p style="margin-left:40%;font-size:10pt;margin-top:9pt;font-family:Times New Roman;margin-bottom:0;border-bottom:0.75pt solid #000000;margin-right:40%;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
   <table style="border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;">
    <tr style="visibility:collapse;">
     <td style="width:20%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:20%;box-sizing:content-box;"/>
     <td style="width:18%;box-sizing:content-box;"/>
     <td style="width:41%;box-sizing:content-box;"/>
    </tr>
    <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;text-align:left;">
     <td colspan="3" style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span><ix:nonNumeric id="F_2df28f37-d62d-4885-ae0e-d18999b774c8" contextRef="C_635a69f0-1a0c-4eb4-9b96-ad916bfa62eb" name="dei:EntityIncorporationStateCountryCode" format="ixt-sec:stateprovnameen"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Delaware</span></ix:nonNumeric></span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span><ix:nonNumeric id="F_dc797436-a410-454a-9919-8bea6e9d5ec5" contextRef="C_635a69f0-1a0c-4eb4-9b96-ad916bfa62eb" name="dei:EntityFileNumber"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">001-36740</span></ix:nonNumeric></span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span><ix:nonNumeric id="F_7ed75dc0-d0d2-4784-bd1e-54d2395efa64" contextRef="C_635a69f0-1a0c-4eb4-9b96-ad916bfa62eb" name="dei:EntityTaxIdentificationNumber"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">77-0357827</span></ix:nonNumeric></span></p></td>
    </tr>
    <tr style="height:7pt;word-break:break-word;white-space:pre-wrap;text-align:left;">
     <td colspan="3" style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">(State or Other Jurisdiction<br/>of Incorporation)</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">(Commission File Number)</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">(IRS Employer<br/>Identification No.)</span></p></td>
    </tr>
    <tr style="word-break:break-word;white-space:pre-wrap;text-align:left;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;text-align:left;">
     <td colspan="3" style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span><ix:nonNumeric id="F_04e8631c-d569-4c8d-8b28-8316940a1d3a" contextRef="C_635a69f0-1a0c-4eb4-9b96-ad916bfa62eb" name="dei:EntityAddressAddressLine1"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">350 Bay Street</span></ix:nonNumeric></span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span><ix:nonNumeric id="F_ee96240a-297a-4a94-a15e-2f9610685039" contextRef="C_635a69f0-1a0c-4eb4-9b96-ad916bfa62eb" name="dei:EntityAddressAddressLine2"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Suite 100 #6009 </span></ix:nonNumeric></span><span></span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
     <td colspan="3" style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span><ix:nonNumeric id="F_155b2fce-ba34-4361-9fb6-51edd9222f5e" contextRef="C_635a69f0-1a0c-4eb4-9b96-ad916bfa62eb" name="dei:EntityAddressCityOrTown"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">San Francisco</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">, </span><span><ix:nonNumeric id="F_87573e3f-76ab-40bc-9e09-3d64d9827ae6" contextRef="C_635a69f0-1a0c-4eb4-9b96-ad916bfa62eb" name="dei:EntityAddressStateOrProvince" format="ixt-sec:stateprovnameen"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">California</span></ix:nonNumeric></span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span><ix:nonNumeric id="F_3e731176-9963-4a76-af3c-4b56676fa64e" contextRef="C_635a69f0-1a0c-4eb4-9b96-ad916bfa62eb" name="dei:EntityAddressPostalZipCode"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">94133</span></ix:nonNumeric></span></p></td>
    </tr>
    <tr style="height:7pt;word-break:break-word;white-space:pre-wrap;text-align:left;">
     <td colspan="3" style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">(Address of Principal Executive Offices)</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">(Zip Code)</span></p></td>
    </tr>
   </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
   <table style="border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;">
    <tr style="visibility:collapse;">
     <td style="width:100%;box-sizing:content-box;"/>
    </tr>
    <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;text-align:left;">
     <td style="padding-top:0.125in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.398%;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Registrant&#8217;s Telephone Number, Including Area Code:</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span><span><ix:nonNumeric id="F_249cb515-c9ff-4245-8c89-5f1e4dc2b3b9" contextRef="C_635a69f0-1a0c-4eb4-9b96-ad916bfa62eb" name="dei:CityAreaCode"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">415</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span><span><ix:nonNumeric id="F_9a66f5ec-2417-4470-a3d4-16e86939f4ee" contextRef="C_635a69f0-1a0c-4eb4-9b96-ad916bfa62eb" name="dei:LocalPhoneNumber"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">978-1200 </span></ix:nonNumeric></span><span></span></p></td>
    </tr>
   </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
   <table style="border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;">
    <tr style="visibility:collapse;">
     <td style="width:100%;box-sizing:content-box;"/>
    </tr>
    <tr style="word-break:break-word;white-space:pre-wrap;text-align:left;">
     <td style="padding-top:0.125in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
   </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:7.5pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(Former Name or Former Address, if Changed Since Last Report)</span></p><p style="margin-left:40%;font-size:10pt;margin-top:9.35pt;font-family:Times New Roman;margin-bottom:0;border-bottom:0.75pt solid #000000;margin-right:40%;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:9.35pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><div style="text-indent:-24.5pt;padding-left:24.5pt;margin-top:3pt;margin-bottom:0;text-align:left;"><span style="margin-right:1em;margin-right:1em;"><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_7f51db64-915f-4368-b917-29581f915908" contextRef="C_635a69f0-1a0c-4eb4-9b96-ad916bfa62eb" name="dei:WrittenCommunications" format="ixt-sec:boolballotbox"><span style="font-size:10pt;font-family:Times New Roman;">&#9744;</span></ix:nonNumeric></span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)</span></div><div style="text-indent:-24.5pt;padding-left:24.5pt;margin-top:6pt;margin-bottom:0;text-align:left;"><span style="margin-right:1em;margin-right:1em;"><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_0a3eaa4a-9ab5-4154-be7f-89636a62518d" contextRef="C_635a69f0-1a0c-4eb4-9b96-ad916bfa62eb" name="dei:SolicitingMaterial" format="ixt-sec:boolballotbox"><span style="font-size:10pt;font-family:Times New Roman;">&#9744;</span></ix:nonNumeric></span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)</span></div><div style="text-indent:-24.5pt;padding-left:24.5pt;margin-top:6pt;margin-bottom:0;text-align:left;"><span style="margin-right:1em;margin-right:1em;"><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_c1a7a408-88aa-4afe-90bd-c8d31a589474" contextRef="C_635a69f0-1a0c-4eb4-9b96-ad916bfa62eb" name="dei:PreCommencementTenderOffer" format="ixt-sec:boolballotbox"><span style="font-size:10pt;font-family:Times New Roman;">&#9744;</span></ix:nonNumeric></span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))</span></div><div style="text-indent:-24.5pt;padding-left:24.5pt;margin-top:6pt;margin-bottom:0;text-align:left;"><span style="margin-right:1em;margin-right:1em;"><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_6f55c0a7-9215-4088-8aa2-4d16530b2733" contextRef="C_635a69f0-1a0c-4eb4-9b96-ad916bfa62eb" name="dei:PreCommencementIssuerTenderOffer" format="ixt-sec:boolballotbox"><span style="font-size:10pt;font-family:Times New Roman;">&#9744;</span></ix:nonNumeric></span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))</span></div><p style="font-size:10pt;margin-top:9pt;font-family:Times New Roman;margin-bottom:9pt;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Securities registered pursuant to Section 12(b) of the Act:</span></p>
   <table style="border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;">
    <tr style="visibility:collapse;">
     <td style="width:38%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:15%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:45%;box-sizing:content-box;"/>
    </tr>
    <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;border-bottom:0.25pt solid;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"><br/>Title of each class</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;border-bottom:0.25pt solid #ffffff03;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;border-bottom:0.25pt solid;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Trading<br/>Symbol(s)</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;border-bottom:0.25pt solid #ffffff03;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;border-bottom:0.25pt solid;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"><br/>Name of each exchange on which registered</span></p></td>
    </tr>
    <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span><ix:nonNumeric id="F_1017a4ec-7005-4735-addd-4b800191c687" contextRef="C_635a69f0-1a0c-4eb4-9b96-ad916bfa62eb" name="dei:Security12bTitle"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Common Stock, $0.01 par value</span></ix:nonNumeric></span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span><ix:nonNumeric id="F_550e9879-b446-44c7-b4eb-1b054ac8091f" contextRef="C_635a69f0-1a0c-4eb4-9b96-ad916bfa62eb" name="dei:TradingSymbol"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">FGEN</span></ix:nonNumeric></span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span><ix:nonNumeric id="F_412972de-18ff-46b8-b58d-b2fe532f91d5" contextRef="C_635a69f0-1a0c-4eb4-9b96-ad916bfa62eb" name="dei:SecurityExchangeName" format="ixt-sec:exchnameen"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">The Nasdaq Global Select Market</span></ix:nonNumeric></span></p></td>
    </tr>
   </table><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (&#167;&#8239;230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (&#167;&#8239;240.12b-2 of this chapter).</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:9pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Emerging growth company </span><span style="font-size:10pt;"><ix:nonNumeric id="F_99ea675d-694e-4ff1-b1b9-2ab3863f94a4" contextRef="C_635a69f0-1a0c-4eb4-9b96-ad916bfa62eb" name="dei:EntityEmergingGrowthCompany" format="ixt-sec:boolballotbox"><span style="font-size:10pt;font-family:Times New Roman;">&#9744;</span></ix:nonNumeric></span></p><p style="font-size:10pt;margin-top:9pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. </span><span style="font-size:10pt;font-family:Times New Roman;">&#9744;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;border-bottom:2.25pt double #000000;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;min-height:0.5in;justify-content:flex-end;position:relative;"></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="z-index:2;min-height:0.5in;position:relative;"></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><h2 style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Item 5.07 Submission of Matters to a Vote of Security Holders.</span></h2><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">At the 2025 annual meeting of stockholders of FibroGen, Inc. (&#8220;FibroGen&#8221; or the &#8220;Company&#8221;) held on June 4, 2025, the stockholders voted on the four proposals listed below. The proposals are described in detail in the Company&#8217;s definitive proxy statement for the 2025 annual meeting of stockholders, filed with the Securities and Exchange Commission on April 25, 2025. The results of the matters voted upon at the meeting were:</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
   <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
    <tr style="visibility:collapse;">
     <td style="width:3%;box-sizing:content-box;"/>
     <td style="width:3%;box-sizing:content-box;"/>
     <td style="width:94%;box-sizing:content-box;"/>
    </tr>
    <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(1)</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">The Class II director nominee, Jeffrey L. Edwards was elected to hold office until the Company&#8217;s 2028 annual meeting of stockholders. The director received 92.25% of the shares voting: 37,865,468 shares of Common Stock voted for, 0 against, 3,179,768 withheld, and 26,318,711 broker non-votes.</span></p><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">The term of office of Class I directors Thane Wettig, James A. Schoeneck, and Maykin Ho, Ph.D. continues until the Company&#8217;s 2027 annual meeting of stockholders.</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    </tr>
    <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(2)</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">The stockholders approved a proposed amendment to our Amended and Restated Certificate of Incorporation to effect a reverse stock split of our outstanding common stock in the range of 1-for-10 to 1-for-25 to enable the Company to comply with Nasdaq stock market&#8217;s continued listing requirements: 56,814,170 shares of Common Stock voted for, 10,105,586 against, and 444,191 abstaining.</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    </tr>
    <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(3)</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">The stockholders approved, on an advisory basis, the compensation of the Company&#8217;s named executive officers, as disclosed in the 2025 definitive proxy statement filed on April 25, 2025: 31,091,508 shares of Common Stock voted for, 8,989,137 against, 964,591 abstaining, and 26,318,711 broker non-votes.</span></p></td>
    </tr>
    <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(4)</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">The stockholders ratified the selection of PricewaterhouseCoopers LLP, by the Audit Committee of the FibroGen board of directors, as the independent registered public accounting firm of the Company for the year ending December 31, 2025: 63,850,073 shares of Common Stock voted for, 2,323,251 against, and 1,190,623 abstaining.</span></p></td>
    </tr>
   </table><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Director Appointment</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Effective June 4, 2025, the Board of the Company, upon recommendation of the Nominating and Corporate Governance Committee, appointed Michael Kauffman, M.D., Ph.D. as a Class III director of the Company. Dr. Kauffman was appointed to the Audit Committee and Compensation Committee of the Board.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">FibroGen is delighted to welcome Dr. Kauffman to the Board. Dr. Kauffman&#8217;s oncology expertise and strategic insight will bring a valuable perspective to the Company as FibroGen focuses on development of novel therapies at the frontiers of cancer biology and anemia.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Dr. Kauffman will hold office for the term expiring 2026.  Dr. Kauffman will receive compensation as a non-employee director of the Company as approved by the Board under the Company&#8217;s Non-Employee Director Compensation Policy, as amended, provided that each of the directors&#8217; annual option grants for 2025, approved by the Board and effective June 4, 2025, will be for 120,000 shares vesting quarterly over the next year, subject to their continued service.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Dr. Kauffman has entered into the Company&#8217;s standard Indemnity Agreement, effective June 4, 2025, a form of which is filed as Exhibit 10.27 with the Company&#8217;s registration statement on Form S-1, as amended, filed with the SEC on October 23, 2014.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">A copy of the Company&#8217;s press release announcing the appointment of Dr. Kauffman to the Board is attached as Exhibit 99.1 to this Current Report on Form 8-K.</span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Director Resignation</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">On June 4, 2025, Aoife Brennan, M.B., B.Ch. provided to the Board of Directors (the &#8220;Board&#8221;) notification of her resignation from the Board of FibroGen, effective June 4, 2025.  Dr. Brennan&#8217;s resignation as director is not the result of any disagreement with the Company or its management on any matter relating to the Company&#8217;s operations, policies, or practices.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Dr. Brennan joined the Company in August 2020 and served in a number of capacities during her tenure with the Company, including as a member of the Audit Committee, and as a member of the Compensation Committee.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company is extremely grateful for Dr. Brennan&#8217;s valuable counsel and direction over the years, and wish her the best in her future endeavors.</span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;min-height:0.5in;justify-content:flex-end;position:relative;"></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="z-index:2;min-height:0.5in;position:relative;"></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Item 1.01 Entry into a Material Definitive Agreement.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">On June 5, 2025, FibroGen entered into the second amendment (&#8220;Second Amendment&#8221;) to the financing agreement, dated as of April 29, 2023 as amended (&#8220;Financing Agreement&#8221;) with investment funds managed by Morgan Stanley Tactical Value, as lenders (the &#8220;Lenders&#8221;) and Wilmington Trust National Association, as administrative agent for the Lenders (the &#8220;Administrative Agent&#8221;). The Second Amendment further reduces the minimum qualified cash balance required to be held in deposit accounts or securities accounts in the United States by the Company from $27 million to $22.5 million.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The foregoing description of the Second Amendment to the Financing Agreement is not complete and is qualified in its entirety by reference to the full text of the Second Amendment, a copy of which is filed herewith as Exhibit 10.1 to this Current Report on Form 8-K and is incorporated herein by reference.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Item 9.01 Financial Statements and Exhibits.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">           (d)    Exhibits</span></p>
   <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
    <tr style="visibility:collapse;">
     <td style="width:11.98%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:87.02%;box-sizing:content-box;"/>
    </tr>
    <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
     <td colspan="3" style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    </tr>
    <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    </tr>
    <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0.02in;padding-left:0.02in;vertical-align:top;padding-bottom:0.02in;border-bottom:0.75pt solid #000000;padding-right:0.02in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Exhibit No.</span></p></td>
     <td style="padding-top:0.02in;padding-left:0.02in;vertical-align:top;padding-bottom:0.02in;border-bottom:0.75pt solid #ffffff03;padding-right:0.02in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">  </span></p></td>
     <td style="padding-top:0.02in;padding-left:0.02in;vertical-align:top;padding-bottom:0.02in;border-bottom:0.75pt solid #000000;padding-right:0.02in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Description</span></p></td>
    </tr>
    <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0.02in;padding-left:0.02in;vertical-align:top;padding-bottom:0.02in;padding-right:0.02in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.1</span></p></td>
     <td style="padding-top:0.02in;padding-left:0.02in;vertical-align:top;padding-bottom:0.02in;padding-right:0.02in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.02in;padding-left:0.02in;vertical-align:top;padding-bottom:0.02in;padding-right:0.02in;text-align:right;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><a href="fgen-ex10_1.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Second Amendment to Financing Agreement by and among FibroGen, Inc., NHTV Fairview Holding LLC, NHTV II Fairview Holding LLC, MSTV Fund II ESC Fairview Holding LLC, and Wilmington Trust, National Association, dated as of June 5, 2025</span></a><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">.</span></p></td>
    </tr>
    <tr style="word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0.02in;padding-left:0.02in;vertical-align:top;padding-bottom:0.02in;padding-right:0.02in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.02in;padding-left:0.02in;vertical-align:top;padding-bottom:0.02in;padding-right:0.02in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.02in;padding-left:0.02in;vertical-align:top;padding-bottom:0.02in;padding-right:0.02in;text-align:right;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0.02in;padding-left:0.02in;vertical-align:top;padding-bottom:0.02in;padding-right:0.02in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">99.1</span></p></td>
     <td style="padding-top:0.02in;padding-left:0.02in;vertical-align:top;padding-bottom:0.02in;padding-right:0.02in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.02in;padding-left:0.02in;vertical-align:top;padding-bottom:0.02in;padding-right:0.02in;text-align:right;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><a href="fgen-ex99_1.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Press Release, dated June 9, 2025</span></a><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">.</span></p></td>
    </tr>
    <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0.02in;padding-left:0.02in;vertical-align:top;padding-bottom:0.02in;padding-right:0.02in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
     <td style="padding-top:0.02in;padding-left:0.02in;vertical-align:top;padding-bottom:0.02in;padding-right:0.02in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
     <td style="padding-top:0.02in;padding-left:0.02in;vertical-align:top;padding-bottom:0.02in;padding-right:0.02in;text-align:right;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    </tr>
    <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0.02in;padding-left:0.02in;vertical-align:top;padding-bottom:0.02in;padding-right:0.02in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">104</span></p></td>
     <td style="padding-top:0.02in;padding-left:0.02in;vertical-align:top;padding-bottom:0.02in;padding-right:0.02in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
     <td style="padding-top:0.02in;padding-left:0.02in;vertical-align:top;padding-bottom:0.02in;padding-right:0.02in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Cover Page Interactive Data File (embedded within the Inline XBRL document).</span></p></td>
    </tr>
   </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;min-height:0.5in;justify-content:flex-end;position:relative;"></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="z-index:2;min-height:0.5in;position:relative;"></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:9.35pt;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">SIGNATURES</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:9.35pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.</span></p>
   <table style="border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;">
    <tr style="visibility:collapse;">
     <td style="width:6%;box-sizing:content-box;"/>
     <td style="width:44%;box-sizing:content-box;"/>
     <td style="width:4%;box-sizing:content-box;"/>
     <td style="width:46%;box-sizing:content-box;"/>
    </tr>
    <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:4.3pt;font-family:Times New Roman;margin-bottom:4.3pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">FibroGen, Inc.</span></p></td>
    </tr>
    <tr style="word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:4.3pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Date:</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:4.3pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">June 9, 2025</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:4.3pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">By:</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;border-bottom:0.25pt solid;padding-right:0in;"><p style="font-size:10pt;margin-top:4.3pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">/s/ John Alden</span></p></td>
    </tr>
    <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0.7pt;font-family:Times New Roman;margin-bottom:9.35pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">John Alden<br/>General Counsel</span></p></td>
    </tr>
   </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;min-height:0.5in;justify-content:flex-end;position:relative;"></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
 </body>
</html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.1
<SEQUENCE>2
<FILENAME>fgen-ex10_1.htm
<DESCRIPTION>EX-10.1
<TEXT>
<html>
 <head>
  <title>EX-10.1</title>
 </head>
 <body style="padding:8px;margin:auto!important;z-index:0;-webkit-text-size-adjust:100%;position:relative;">
  <div style="padding-top:0.5in;z-index:2;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:24pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">[*] = Certain confidential information contained in this document, marked by brackets, has been omitted because it is both (i) not material and (ii) would likely cause competitive harm to the company if publicly disclosed.</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Exhibit 10.1</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">SECOND AMENDMENT TO FINANCING AGREEMENT</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">This SECOND AMENDMENT TO FINANCING AGREEMENT (this &#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Amendment</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d;), dated as of June 5, 2025, is entered into among FIBROGEN, INC., a Delaware corporation (the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Borrower</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d;), the lenders party hereto constituting Required Lenders under the Financing Agreement (the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Lenders</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d;), and Wilmington Trust, National Association, as administrative agent for the Lenders (in such capacity, the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Agent</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d;).</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:center;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">RECITALS</font></p><p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Borrower, the Guarantors party thereto, the lenders from time to time party thereto, and the Agent are parties to that certain Financing Agreement, dated as of April 29, 2023 (as amended by the First Amendment to Financing Agreement dated as of May 8, 2025 and as otherwise amended, restated, supplemented or otherwise modified from time to time prior to the date hereof, the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Financing Agreement</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d;; capitalized terms used herein and not defined shall have the meanings ascribed to them in the Financing Agreement or the Financing Agreement as amended hereby (the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Amended Financing Agreement</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d;), as applicable). The Borrower has requested that Agent and the Required Lenders make certain changes to the Financing Agreement.  The Agent and the Required Lenders have agreed to such requests, subject to the terms and conditions set forth herein.</font></p><p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Accordingly, in consideration of the premises and the mutual agreements contained herein, the parties hereto hereby agree as follows:</font></p><p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">SECTION 1.     </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Amendments to Financing Agreement</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.  Effective as of the Second Amendment Effective Date (as defined below), the Financing Agreement is hereby amended as follows:</font></p><p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(a)     Section 6.8 of the Financing Agreement is hereby amended and restated, in its entirety, as follows:</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p><p style="text-indent:13.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 6.8     </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Minimum Qualified Cash</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.  The Loan Parties shall not permit the aggregate amount of Qualified Cash in Deposit Accounts or Securities Accounts located in the United States as of each Interest Payment Date (after giving pro forma effect to the interest payment due and payable on such date) to be less than $22,500,000.</font></p><p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(b)     Footnote 2 to Annex A to Exhibit B of the Financing Agreement is hereby amended and restated, in its entirety, as follows:</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p><p style="margin-left:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Qualified Cash located in the United States as of the Interest Payment Date (after giving pro forma effect to the interest payment due and payable on such date) to not be less than $22,500,000.</font></p><p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">SECTION 2.     </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Conditions Precedent</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.  This Amendment shall become effective upon Agent&#x2019;s receipt of a copy of this Amendment duly executed by the Borrower, the Agent and the Required Lenders (the date of effectiveness, the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Second Amendment Effective Date</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d;).</font></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">[*] = Certain confidential information contained in this document, marked by brackets, has been omitted because it is both (i) not material and (ii) would likely cause competitive harm to the company if publicly disclosed.</font></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.5in;z-index:2;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">SECTION 3.     </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Reference to and Effect on the Financing Agreement and the Other Loan Documents</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">  </font></p><p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(a)     Upon the effectiveness of this Amendment, each reference in the Financing Agreement to &#x201c;this Agreement,&#x201d; &#x201c;hereunder,&#x201d; &#x201c;hereof,&#x201d; &#x201c;herein&#x201d; or words of like import referring to the Financing Agreement, and each reference in the other Loan Documents to &#x201c;the Financing Agreement,&#x201d; &#x201c;thereunder,&#x201d; &#x201c;thereof,&#x201d; &#x201c;therein&#x201d; or words of like import referring to the Financing Agreement, shall mean and be a reference to the Amended Financing Agreement.</font></p><p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(b)     Except as specifically amended herein, the Financing Agreement and all other Loan Documents are and shall continue to be in full force and effect and are hereby in all respects ratified and confirmed.</font></p><p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(c)     The execution, delivery and effectiveness of this Amendment shall not operate as a waiver of any right, power or remedy of the Agent or the Lenders under the Financing Agreement or any other Loan Documents, constitute a waiver of any provision of the Financing Agreement or any other Loan Documents, or serve to effect a novation of the Obligations.</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">  </font></p><p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">SECTION 4.     </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Execution in Counterparts; Integration</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.  This Amendment may be executed in any number of counterparts and by different parties hereto in separate counterparts, each of which when so executed and delivered shall be deemed to be an original and all of which taken together shall constitute but one and the same agreement.  Delivery of an executed counterpart of a signature page to this Amendment electronically shall be effective as delivery of a manually executed counterpart of this Amendment.  This Amendment, together with the other Loan Documents, represents the entire agreement of the Borrower, the Lenders and the Agent with respect to the subject matter hereof, and there are no promises, undertakings, representations or warranties by the Agent or any Lender relative to the subject matter hereof not expressly set forth or referred to herein or in the other Loan Documents.</font></p><p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">SECTION 4.     </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;text-decoration:underline solid;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">GOVERNING LAW</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.  THIS AMENDMENT AND THE RIGHTS AND OBLIGATIONS OF THE PARTIES UNDER THIS AMENDMENT SHALL BE GOVERNED BY, AND SHALL BE CONSTRUED AND ENFORCED IN ACCORDANCE WITH, THE LAW OF THE STATE OF NEW YORK APPLICABLE TO CONTRACTS MADE AND TO BE PERFORMED IN THE STATE OF NEW YORK.</font></p><p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">SECTION 5.     </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Headings</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.  Section headings herein are included for convenience of reference only and shall not constitute a part of this Amendment for any other purpose.</font></p><p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">SECTION 6.     </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Incorporation by Reference</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.  The terms and provisions of Sections 10.17 (&#x201c;CONSENT TO JURISDICTION&#x201d;) and 10.18 (&#x201c;WAIVER OF JURY TRIAL&#x201d;) of the Financing Agreement are hereby incorporated herein by reference, </font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">mutatis mutandis</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, with the same force and effect as if fully set forth herein, and the parties hereto agree to such terms.  This Amendment constitutes a &#x201c;Loan Document&#x201d; under and as defined in the Financing Agreement and is subject to the terms and provisions therein regarding Loan Documents.</font></p><p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">SECTION 7.     </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Required Lender Authorization</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. By its execution hereof, each of the undersigned Lenders hereby authorizes and directs the Agent to execute and deliver this Amendment on the date hereof.</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:24pt;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">[SIGNATURE PAGES FOLLOW]</font></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">- </font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">2</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> -</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">[*] = Certain confidential information contained in this document, marked by brackets, has been omitted because it is both (i) not material and (ii) would likely cause competitive harm to the company if publicly disclosed.</font></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.5in;z-index:2;min-height:0.7in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:24pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">IN WITNESS WHEREOF, the parties hereto have caused this Amendment to be duly executed and delivered by their proper and duly authorized officers as of the date hereof.</font></p>
   <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:50.0%;border-collapse:separate;">
    <tr style="visibility:collapse;">
     <td style="width:16.92%;box-sizing:content-box;"></td>
     <td style="width:83.08%;box-sizing:content-box;"></td>
    </tr>
    <tr style="height:11pt;word-break:break-word;white-space:pre-wrap;">
     <td colspan="2" style="padding-top:0in;padding-left:0.075in;vertical-align:top;padding-bottom:0in;padding-right:0.075in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;" id="ole_link2"><font id="ole_link1"></font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">FIBROGEN, INC.</font><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">,</font></p></td>
    </tr>
    <tr style="height:11pt;word-break:break-word;white-space:pre-wrap;">
     <td colspan="2" style="padding-top:0in;padding-left:0.075in;vertical-align:top;padding-bottom:0in;padding-right:0.075in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">as Borrower</font></p><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    </tr>
    <tr style="height:11pt;word-break:break-word;white-space:pre-wrap;text-align:right;">
     <td style="padding-top:0in;padding-left:0.075in;vertical-align:top;padding-bottom:0in;padding-right:0.075in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">By:</font></p></td>
     <td style="padding-top:0in;padding-left:0.075in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid;padding-right:0.075in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">/s/ [*]</font></p></td>
    </tr>
    <tr style="height:11pt;word-break:break-word;white-space:pre-wrap;text-align:right;">
     <td colspan="2" style="padding-top:0in;text-indent:39.6pt;padding-left:0.075in;vertical-align:top;padding-bottom:0in;padding-right:0.075in;"><p style="margin-left:7.333%;text-indent:0;font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Name: [*]</font></p></td>
    </tr>
    <tr style="height:11pt;word-break:break-word;white-space:pre-wrap;text-align:right;">
     <td colspan="2" style="padding-top:0in;text-indent:39.6pt;padding-left:0.075in;vertical-align:top;padding-bottom:0in;padding-right:0.075in;"><p style="margin-left:7.333%;text-indent:0;font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Title: [*]</font></p><p style="margin-left:7.333%;text-indent:0;font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    </tr>
   </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.7in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">[*] = Certain confidential information contained in this document, marked by brackets, has been omitted because it is both (i) not material and (ii) would likely cause competitive harm to the company if publicly disclosed.</font></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.5in;z-index:2;min-height:0.7in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
   <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:50.0%;border-collapse:separate;">
    <tr style="visibility:collapse;">
     <td style="width:16.92%;box-sizing:content-box;"></td>
     <td style="width:83.08%;box-sizing:content-box;"></td>
    </tr>
    <tr style="height:11pt;word-break:break-word;white-space:pre-wrap;">
     <td colspan="2" style="padding-top:0in;padding-left:0.075in;vertical-align:top;padding-bottom:0in;padding-right:0.075in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">WILMINGTON TRUST, NATIONAL ASSOCIATION</font><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">,</font></p></td>
    </tr>
    <tr style="height:11pt;word-break:break-word;white-space:pre-wrap;">
     <td colspan="2" style="padding-top:0in;padding-left:0.075in;vertical-align:top;padding-bottom:0in;padding-right:0.075in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">as Agent</font></p><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    </tr>
    <tr style="height:11pt;word-break:break-word;white-space:pre-wrap;text-align:right;">
     <td style="padding-top:0in;padding-left:0.075in;vertical-align:top;padding-bottom:0in;padding-right:0.075in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">By:</font></p></td>
     <td style="padding-top:0in;padding-left:0.075in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid;padding-right:0.075in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">/s/ [*]</font></p></td>
    </tr>
    <tr style="height:11pt;word-break:break-word;white-space:pre-wrap;text-align:right;">
     <td colspan="2" style="padding-top:0in;text-indent:39.6pt;padding-left:0.075in;vertical-align:top;padding-bottom:0in;padding-right:0.075in;"><p style="margin-left:7.333%;text-indent:0;font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Name: [*]</font></p></td>
    </tr>
    <tr style="height:11pt;word-break:break-word;white-space:pre-wrap;text-align:right;">
     <td colspan="2" style="padding-top:0in;text-indent:39.6pt;padding-left:0.075in;vertical-align:top;padding-bottom:0in;padding-right:0.075in;"><p style="margin-left:7.333%;text-indent:0;font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Title: [*]</font></p></td>
    </tr>
   </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.7in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">[Signature Page to Second Amendment]</font></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">[*] = Certain confidential information contained in this document, marked by brackets, has been omitted because it is both (i) not material and (ii) would likely cause competitive harm to the company if publicly disclosed.</font></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.5in;z-index:2;min-height:0.7in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;">
   <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:50.0%;border-collapse:separate;">
    <tr style="visibility:collapse;">
     <td style="width:16.92%;box-sizing:content-box;"></td>
     <td style="width:83.08%;box-sizing:content-box;"></td>
    </tr>
    <tr style="height:11pt;word-break:break-word;white-space:pre-wrap;">
     <td colspan="2" style="padding-top:0in;padding-left:0.075in;vertical-align:top;padding-bottom:0in;padding-right:0.075in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">NHTV Fairview Holding LLC,</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </font></p></td>
    </tr>
    <tr style="height:11pt;word-break:break-word;white-space:pre-wrap;">
     <td colspan="2" style="padding-top:0in;padding-left:0.075in;vertical-align:top;padding-bottom:0in;padding-right:0.075in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">as Lender</font></p><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    </tr>
    <tr style="height:11pt;word-break:break-word;white-space:pre-wrap;text-align:right;">
     <td style="padding-top:0in;padding-left:0.075in;vertical-align:top;padding-bottom:0in;padding-right:0.075in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">By:</font></p></td>
     <td style="padding-top:0in;padding-left:0.075in;vertical-align:top;padding-bottom:0in;padding-right:0.075in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">North Haven Tactical Value Fund LP,</font></p><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">its sole member</font></p><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    </tr>
    <tr style="height:11pt;word-break:break-word;white-space:pre-wrap;text-align:right;">
     <td style="padding-top:0in;padding-left:0.075in;vertical-align:top;padding-bottom:0in;padding-right:0.075in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">By:</font></p></td>
     <td style="padding-top:0in;padding-left:0.075in;vertical-align:top;padding-bottom:0in;padding-right:0.075in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">MS Tactical Value Fund GP LP,</font><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </font></p><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">its general partner</font></p></td>
    </tr>
    <tr style="height:11pt;word-break:break-word;white-space:pre-wrap;text-align:right;">
     <td style="padding-top:0in;padding-left:0.075in;vertical-align:top;padding-bottom:0in;padding-right:0.075in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">By:</font></p></td>
     <td style="padding-top:0in;padding-left:0.075in;vertical-align:top;padding-bottom:0in;padding-right:0.075in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">MS Tactical Value Fund GP Inc.,</font></p><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">its general partner</font></p></td>
    </tr>
    <tr style="height:38.15pt;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0in;padding-left:0.075in;vertical-align:bottom;padding-bottom:0in;padding-right:0.075in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">By:</font></p></td>
     <td style="padding-top:0in;padding-left:0.075in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid;padding-right:0.075in;text-align:right;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">/s/ [*]</font></p></td>
    </tr>
    <tr style="height:11pt;word-break:break-word;white-space:pre-wrap;text-align:right;">
     <td colspan="2" style="padding-top:0in;text-indent:39.6pt;padding-left:0.075in;vertical-align:top;padding-bottom:0in;padding-right:0.075in;"><p style="margin-left:7.333%;text-indent:0;font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Name: [*]</font></p></td>
    </tr>
    <tr style="height:11pt;word-break:break-word;white-space:pre-wrap;text-align:right;">
     <td colspan="2" style="padding-top:0in;text-indent:39.6pt;padding-left:0.075in;vertical-align:top;padding-bottom:0in;padding-right:0.075in;"><p style="margin-left:7.333%;text-indent:0;font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Title: [*]</font></p></td>
    </tr>
    <tr style="word-break:break-word;white-space:pre-wrap;text-align:right;">
     <td colspan="2" style="padding-top:0in;text-indent:39.6pt;padding-left:0.075in;vertical-align:top;padding-bottom:0in;padding-right:0.075in;"><p style="margin-left:7.333%;text-indent:0;font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    </tr>
    <tr style="word-break:break-word;white-space:pre-wrap;text-align:right;">
     <td colspan="2" style="padding-top:0in;text-indent:39.6pt;padding-left:0.075in;vertical-align:top;padding-bottom:0in;padding-right:0.075in;"><p style="margin-left:7.333%;text-indent:0;font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    </tr>
    <tr style="height:11pt;word-break:break-word;white-space:pre-wrap;">
     <td colspan="2" style="padding-top:0in;padding-left:0.075in;vertical-align:top;padding-bottom:0in;padding-right:0.075in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">NHTV II Fairview Holding LLC,</font></p></td>
    </tr>
    <tr style="height:11pt;word-break:break-word;white-space:pre-wrap;">
     <td colspan="2" style="padding-top:0in;padding-left:0.075in;vertical-align:top;padding-bottom:0in;padding-right:0.075in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">as Lender</font></p><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    </tr>
    <tr style="height:11pt;word-break:break-word;white-space:pre-wrap;text-align:right;">
     <td style="padding-top:0in;padding-left:0.075in;vertical-align:top;padding-bottom:0in;padding-right:0.075in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">By:</font></p></td>
     <td style="padding-top:0in;padding-left:0.075in;vertical-align:top;padding-bottom:0in;padding-right:0.075in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">NHTV II Onshore Aggregator LP,</font><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </font></p><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">its sole member</font></p></td>
    </tr>
    <tr style="height:11pt;word-break:break-word;white-space:pre-wrap;text-align:right;">
     <td style="padding-top:0in;padding-left:0.075in;vertical-align:top;padding-bottom:0in;padding-right:0.075in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">By:</font></p></td>
     <td style="padding-top:0in;padding-left:0.075in;vertical-align:top;padding-bottom:0in;padding-right:0.075in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">MS Tactical Value Fund II GP LP,</font><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </font></p><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">its general partner</font></p></td>
    </tr>
    <tr style="height:11pt;word-break:break-word;white-space:pre-wrap;text-align:right;">
     <td style="padding-top:0in;padding-left:0.075in;vertical-align:top;padding-bottom:0in;padding-right:0.075in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">By:</font></p></td>
     <td style="padding-top:0in;padding-left:0.075in;vertical-align:top;padding-bottom:0in;padding-right:0.075in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">MS Tactical Value Fund II GP Inc.,</font><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </font></p><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">its general partner</font></p></td>
    </tr>
    <tr style="height:36.7pt;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0in;padding-left:0.075in;vertical-align:bottom;padding-bottom:0in;padding-right:0.075in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">By:</font></p></td>
     <td style="padding-top:0in;padding-left:0.075in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid;padding-right:0.075in;text-align:right;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">/s/ [*]</font></p></td>
    </tr>
    <tr style="height:11pt;word-break:break-word;white-space:pre-wrap;text-align:right;">
     <td colspan="2" style="padding-top:0in;text-indent:39.6pt;padding-left:0.075in;vertical-align:top;padding-bottom:0in;padding-right:0.075in;"><p style="margin-left:7.333%;text-indent:0;font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Name: [*]</font></p></td>
    </tr>
    <tr style="height:11pt;word-break:break-word;white-space:pre-wrap;text-align:right;">
     <td colspan="2" style="padding-top:0in;text-indent:39.6pt;padding-left:0.075in;vertical-align:top;padding-bottom:0in;padding-right:0.075in;"><p style="margin-left:7.333%;text-indent:0;font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Title: [*]</font></p></td>
    </tr>
   </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.7in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">[Signature Page to Second Amendment]</font></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">[*] = Certain confidential information contained in this document, marked by brackets, has been omitted because it is both (i) not material and (ii) would likely cause competitive harm to the company if publicly disclosed.</font></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.5in;z-index:2;min-height:0.7in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
   <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:50.0%;border-collapse:separate;">
    <tr style="visibility:collapse;">
     <td style="width:11.28%;box-sizing:content-box;"></td>
     <td style="width:88.72%;box-sizing:content-box;"></td>
    </tr>
    <tr style="height:11pt;word-break:break-word;white-space:pre-wrap;">
     <td colspan="2" style="padding-top:0in;padding-left:0.075in;vertical-align:top;padding-bottom:0in;padding-right:0.075in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">MSTV Fund II ESC Fairview Holding LLC</font><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">,</font></p></td>
    </tr>
    <tr style="height:23.05pt;word-break:break-word;white-space:pre-wrap;">
     <td colspan="2" style="padding-top:0in;padding-left:0.075in;vertical-align:top;padding-bottom:0in;padding-right:0.075in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">as Lender</font></p></td>
    </tr>
    <tr style="height:35.3pt;word-break:break-word;white-space:pre-wrap;text-align:right;">
     <td style="padding-top:0in;padding-left:0.075in;vertical-align:top;padding-bottom:0in;padding-right:0.075in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">By:</font></p></td>
     <td style="padding-top:0in;padding-left:0.075in;vertical-align:top;padding-bottom:0in;padding-right:0.075in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">MSTV Fund II Employees Investments LP,</font><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </font></p><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">its sole member</font></p></td>
    </tr>
    <tr style="height:39.6pt;word-break:break-word;white-space:pre-wrap;text-align:right;">
     <td style="padding-top:0in;padding-left:0.075in;vertical-align:top;padding-bottom:0in;padding-right:0.075in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">By:</font></p></td>
     <td style="padding-top:0in;padding-left:0.075in;vertical-align:top;padding-bottom:0in;padding-right:0.075in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">MS Tactical Value Fund II GP LP,</font><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </font></p><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">its general partner</font></p></td>
    </tr>
    <tr style="height:11pt;word-break:break-word;white-space:pre-wrap;text-align:right;">
     <td style="padding-top:0in;padding-left:0.075in;vertical-align:top;padding-bottom:0in;padding-right:0.075in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">By:</font></p></td>
     <td style="padding-top:0in;padding-left:0.075in;vertical-align:top;padding-bottom:0in;padding-right:0.075in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">MS Tactical Value Fund II GP Inc.,</font><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </font></p><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">its general partner</font></p></td>
    </tr>
    <tr style="height:33.85pt;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0in;padding-left:0.075in;vertical-align:bottom;padding-bottom:0in;padding-right:0.075in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">By:</font></p></td>
     <td style="padding-top:0in;padding-left:0.075in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid;padding-right:0.075in;text-align:right;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">/s/ [*]</font></p></td>
    </tr>
    <tr style="height:11pt;word-break:break-word;white-space:pre-wrap;text-align:right;">
     <td colspan="2" style="padding-top:0in;text-indent:39.6pt;padding-left:0.075in;vertical-align:top;padding-bottom:0in;padding-right:0.075in;"><p style="margin-left:7.333%;text-indent:0;font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Name: [*]</font></p></td>
    </tr>
    <tr style="height:11pt;word-break:break-word;white-space:pre-wrap;text-align:right;">
     <td colspan="2" style="padding-top:0in;text-indent:39.6pt;padding-left:0.075in;vertical-align:top;padding-bottom:0in;padding-right:0.075in;"><p style="margin-left:7.333%;text-indent:0;font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Title: [*]</font></p></td>
    </tr>
   </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.7in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">[Signature Page to Second Amendment]</font></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">[*] = Certain confidential information contained in this document, marked by brackets, has been omitted because it is both (i) not material and (ii) would likely cause competitive harm to the company if publicly disclosed.</font></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
 </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>3
<FILENAME>fgen-ex99_1.htm
<DESCRIPTION>EX-99.1
<TEXT>
<html>
 <head>
  <title>EX-99.1</title>
 </head>
 <body style="padding:8px;margin:auto!important;z-index:0;-webkit-text-size-adjust:100%;position:relative;">
  <div style="z-index:2;min-height:0.5in;position:relative;"></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:8pt;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Exhibit 99.1</font></p><p style="margin-left:0.84%;text-indent:-3.623%;padding-left:3.467%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><img src="img3914235_0.jpg" alt="img3914235_0.jpg" style="width:178px;height:45px;"></p><p style="margin-left:0.84%;text-indent:-3.623%;padding-left:3.467%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;font-size:14pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="margin-left:0.84%;text-indent:-3.623%;padding-left:3.467%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:14pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">FibroGen Appoints Michael Kauffman, M.D., Ph.D. to its Board of Directors</font></p><p style="margin-left:0.84%;text-indent:-3.623%;padding-left:3.467%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;font-size:14pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">SAN FRANCISCO, June 9, 2025 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ: FGEN) today announced the appointment of Dr. Michael Kauffman to its Board of Directors effective June 4, 2025.</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;Michael is a well-recognized biotech industry veteran, who brings a wealth of biotech leadership experience to our board,&#x201d; said James Schoeneck, chairman of the board of directors of FibroGen. &#x201c;His expertise spanning all stages of drug development will be invaluable as FibroGen progresses its pipeline. Michael&#x2019;s deep understanding of oncology will help the company through anticipated near-term clinical milestones and potential value-drivers.&#x201d;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;FibroGen has differentiated potential first-in-class assets and the company is positioning itself for a significant turnaround over the next several years,&#x201d; said Dr. Kauffman. &#x201c;It is an honor to join the board at this exciting time for the company, and I look forward to contributing to the company&#x2019;s future success.&#x201d;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">	</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Michael Kauffman, M.D., Ph.D.</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Michael G. Kauffman, M.D., Ph.D. has about 30 years of experience in the life sciences industry, particularly in oncology therapeutic products, including expertise in preclinical research, clinical development, regulatory strategy and global approvals. He currently serves as chief executive officer (CEO), president, and board member of Nereid Therapeutics Inc. and is the Lead Director on the board of Verastem Oncology. In addition to Verastem Oncology and Nereid, he is a board member for FoRx Therapeutics, Kezar Life Sciences, Incendia Therapeutics, and BiVictriX Therapeutics. Previously, Dr Kauffman served as the co-founder and CEO of Karyopharm, where he guided the Company's transition from a discovery stage biotechnology company to a commercial stage organization and the global approvals of XPOVIO&#174;. Prior to joining Karyopharm, Dr Kauffman was CMO of Onyx Pharma, where he led the development of Kyprolis&#174; following the Onyx acquisition of Proteolix Inc., where he served as board member and then CMO. Previously, Dr. Kauffman was President and Chief Executive officer of EPIX Pharmaceuticals, Inc. (previously Predix Pharmaceuticals, Inc.). Before that, he was the leader of the Velcade&#174; development program at Millennium Pharmaceuticals and has also held a number of senior positions at Millennium Predictive Medicine and Biogen. Dr Kauffman received his MD and PhD from Johns Hopkins Medical School, trained in Internal Medicine at Beth Israel (Deaconess) Medical Center and in Rheumatology at Massachusetts General Hospital, and is board certified in Internal Medicine.</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.3in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="z-index:2;min-height:0.5in;position:relative;"></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">About FibroGen</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">  </font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">FibroGen, Inc. is a biopharmaceutical company focused on development of novel therapies at the frontiers of cancer biology and anemia. Roxadustat (&#x7231;&#x745e;&#x5353;</font><font style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:8.040000000000001pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#174;</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, EVRENZO</font><font style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:8.040000000000001pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">TM</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">) is currently approved in China, Europe, Japan, and numerous other countries for the treatment of anemia in chronic kidney disease (CKD) patients on dialysis and not on dialysis. The Company continues to evaluate a development plan for roxadustat in anemia associated with lower-risk myelodysplastic syndrome (LR-MDS) in the U.S. FG-3246 (also known as FOR46), a first-in-class antibody-drug conjugate (ADC) targeting CD46 is in development for the treatment of metastatic castration-resistant prostate cancer. This program also includes the development of FG-3180, an associated CD46-targeted PET biomarker. For more information, please visit </font><font><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">www.fibrogen.com</font></font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">For Investor Inquiries:</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">David DeLucia, CFA</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Senior Vice President and Chief Financial Officer</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">ir@fibrogen.com</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.3in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
 </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>4
<FILENAME>img3914235_0.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img3914235_0.jpg
M_]C_X  02D9)1@ ! 0$ W #<  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" !G 9@# 2(  A$! Q$!_\0
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M<OS$<X'I5JSW.>I.I'6*N>LMTKSN:TU+0-8UK5?"\/\ :5JLB1W&A>?L5I
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M8H^WW(Y,1*DYCC(PPSAG&,D YY*Z^,'_  D6I6?@_6K2?P9?79:._GN)P$
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MU4S1N%?FE^Q3X\^+WQ0^,UI#)XYUN_\ #]@GVG5A?W)N(C$#Q& ^<%VP,C!
MR:]I_:>_;RM/AEJUYX6\#P6^L^(8,QW6HS'=;6C]T4 _/(._8'@YY%9RP\U/
MV:U9:JQY>9GV)NI-U?C?XF_:V^+WBJ[$\_CO5K,KG$>ER?9$Y/<1XS^-='X#
M_;F^+G@F: 2Z^/$=E$</;:S&)6<9[R#Y_P <UM]2J6T9"Q$3];J@NKN&RMYK
MBXE6&"%#)))(=JHH&22>P KR3]G3]I+P]^T+X;DNM/4Z=K=J!]NTF1]SPY.
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M'ZKD<94U^G/[*?Q%G^)G[-.CZA=DM?V=I+IURQ!PSQ*55@2><ILR?7-?%O\
MP4:UBRU3]H**WM)4EFL-(@M[G8>4DWR.$/H0KJ?^!5]+_P#!/NWDA_9AO'<D
MK+?WC(#V&Q1_,5ZE>\Z$)RW..G[M221^8]O;R74T<$*&2:601HH&<L3@"OU6
M^ _[%'@/X>>#[,>(]!L?%/B.XB66\N=3@6:.-V )CC1A@*IX!QD\\\X'YA^
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M"1K&S,S=  #DUYL:DXRYKZG5*,6K6/Q=^ OQ-O?@[\6] \10?*D%R+>\@D)
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M2W]Q+)A3*R!B,X''0=J_*+XF6-OI?Q&\5V5K$MO:V^J7444,8PL:"5@J@>P
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1%% !1110 4444 %%%% '_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>5
<FILENAME>fgen-20250604.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!-- DFIN New ActiveDisclosure (SM) XBRL Schema Document - http://www.dfinsolutions.com/ -->
<!-- Creation Date :2025-06-09T15:55:50.3508+00:00 -->
<!-- Copyright (c) 2025 Donnelley Financial Solutions, Inc. All Rights Reserved. -->
<xsd:schema targetNamespace="http://www.fibrogen.com/20250604" attributeFormDefault="unqualified" elementFormDefault="qualified" xmlns:enum2="http://xbrl.org/2020/extensible-enumerations-2.0" xmlns:fgen="http://www.fibrogen.com/20250604" xmlns:xsd="http://www.w3.org/2001/XMLSchema" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:us-gaap="http://fasb.org/us-gaap/2025" xmlns:dei="http://xbrl.sec.gov/dei/2025" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xlink="http://www.w3.org/1999/xlink">
  <xsd:import schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" namespace="http://www.xbrl.org/2003/instance"/>
  <xsd:import schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" namespace="http://www.xbrl.org/2003/linkbase"/>
  <xsd:import schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd" namespace="http://xbrl.org/2005/xbrldt"/>
  <xsd:import schemaLocation="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd" namespace="http://fasb.org/us-gaap/2025"/>
  <xsd:import schemaLocation="https://xbrl.sec.gov/dei/2025/dei-2025.xsd" namespace="http://xbrl.sec.gov/dei/2025"/>
  <xsd:annotation>
    <xsd:appinfo>
      <link:roleType roleURI="http://www.fibrogen.com/20250604/taxonomy/role/DocumentDocumentAndEntityInformation" id="Role_DocumentDocumentAndEntityInformation">
        <link:definition>100000 - Document - Document And Entity Information</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:linkbase id="lnk">
        <link:roleRef roleURI="http://www.fibrogen.com/20250604/taxonomy/role/DocumentDocumentAndEntityInformation" xlink:href="fgen-20250604.xsd#Role_DocumentDocumentAndEntityInformation" xlink:type="simple"/>
        <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:title="labelLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CoverAbstract" xlink:label="dei_CoverAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentType" xlink:label="dei_DocumentType"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressAddressLine2" xlink:label="dei_EntityAddressAddressLine2"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="dei_PreCommencementIssuerTenderOffer"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_PreCommencementTenderOffer" xlink:label="dei_PreCommencementTenderOffer"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_SolicitingMaterial" xlink:label="dei_SolicitingMaterial"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_WrittenCommunications" xlink:label="dei_WrittenCommunications"/>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_CoverAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cover [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_AmendmentFlag_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Amendment Flag</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_CityAreaCode_lbl" xlink:role="http://www.xbrl.org/2003/role/label">City Area Code</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentPeriodEndDate_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Document Period End Date</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentType_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Document Type</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressAddressLine1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, Address Line One</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressAddressLine2_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, Address Line Two</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressCityOrTown_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, City or Town</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressPostalZipCode_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, Postal Zip Code</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressStateOrProvince_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, State or Province</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityCentralIndexKey_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Central Index Key</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Emerging Growth Company</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityFileNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity File Number</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Incorporation, State or Country Code</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityRegistrantName_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Registrant Name</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Tax Identification Number</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_LocalPhoneNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Local Phone Number</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_PreCommencementIssuerTenderOffer_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Pre-commencement Issuer Tender Offer</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_PreCommencementTenderOffer_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Pre-commencement Tender Offer</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_Security12bTitle_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Title of 12(b) Security</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_SecurityExchangeName_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Security Exchange Name</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_SolicitingMaterial_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Soliciting Material</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_TradingSymbol_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Trading Symbol</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_WrittenCommunications_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Written Communications</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CoverAbstract" xlink:to="dei_CoverAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CityAreaCode" xlink:to="dei_CityAreaCode_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine1" xlink:to="dei_EntityAddressAddressLine1_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine2" xlink:to="dei_EntityAddressAddressLine2_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCityOrTown" xlink:to="dei_EntityAddressCityOrTown_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressPostalZipCode" xlink:to="dei_EntityAddressPostalZipCode_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressStateOrProvince" xlink:to="dei_EntityAddressStateOrProvince_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFileNumber" xlink:to="dei_EntityFileNumber_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityTaxIdentificationNumber" xlink:to="dei_EntityTaxIdentificationNumber_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LocalPhoneNumber" xlink:to="dei_LocalPhoneNumber_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementIssuerTenderOffer" xlink:to="dei_PreCommencementIssuerTenderOffer_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementTenderOffer" xlink:to="dei_PreCommencementTenderOffer_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12bTitle" xlink:to="dei_Security12bTitle_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityExchangeName" xlink:to="dei_SecurityExchangeName_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SolicitingMaterial" xlink:to="dei_SolicitingMaterial_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_TradingSymbol" xlink:to="dei_TradingSymbol_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_WrittenCommunications" xlink:to="dei_WrittenCommunications_lbl"/>
        </link:labelLink>
        <link:presentationLink xlink:role="http://www.fibrogen.com/20250604/taxonomy/role/DocumentDocumentAndEntityInformation" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CoverAbstract" xlink:label="dei_CoverAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentType" xlink:label="dei_DocumentType"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressAddressLine2" xlink:label="dei_EntityAddressAddressLine2"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="dei_PreCommencementIssuerTenderOffer"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_PreCommencementTenderOffer" xlink:label="dei_PreCommencementTenderOffer"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_SolicitingMaterial" xlink:label="dei_SolicitingMaterial"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_WrittenCommunications" xlink:label="dei_WrittenCommunications"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_AmendmentFlag" order="10010.0" priority="2" use="optional"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_CityAreaCode" order="10130.0" priority="2" use="optional"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentPeriodEndDate" order="10020.0" priority="2" use="optional"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentType" order="10000.0" priority="2" use="optional"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressAddressLine1" order="10090.0" priority="2" use="optional"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressAddressLine2" order="10091.0" priority="2" use="optional"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressCityOrTown" order="10100.0" priority="2" use="optional"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressPostalZipCode" order="10120.0" priority="2" use="optional"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressStateOrProvince" order="10110.0" priority="2" use="optional"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityCentralIndexKey" order="10040.0" priority="2" use="optional"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityEmergingGrowthCompany" order="10050.0" priority="2" use="optional"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityFileNumber" order="10060.0" priority="2" use="optional"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityIncorporationStateCountryCode" order="10070.0" priority="2" use="optional"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityRegistrantName" order="10030.0" priority="2" use="optional"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityTaxIdentificationNumber" order="10080.0" priority="2" use="optional"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_LocalPhoneNumber" order="10140.0" priority="2" use="optional"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_PreCommencementIssuerTenderOffer" order="10190.0" priority="2" use="optional"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_PreCommencementTenderOffer" order="10180.0" priority="2" use="optional"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_Security12bTitle" order="10210.0" priority="2" use="optional"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_SecurityExchangeName" order="10340.0" priority="2" use="optional"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_SolicitingMaterial" order="10170.0" priority="2" use="optional"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_TradingSymbol" order="10220.0" priority="2" use="optional"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_WrittenCommunications" order="10160.0" priority="2" use="optional"/>
        </link:presentationLink>
      </link:linkbase>
    </xsd:appinfo>
  </xsd:annotation>
</xsd:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>7
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Document And Entity Information<br></strong></div></th>
<th class="th"><div>Jun. 04, 2025</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">8-K<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Jun.  04,  2025<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">FIBROGEN, INC.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0000921299<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-36740<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">77-0357827<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">350 Bay Street<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine2', window );">Entity Address, Address Line Two</a></td>
<td class="text">Suite 100 #6009 <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">San Francisco<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">CA<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">94133<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">415<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">978-1200 <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_WrittenCommunications', window );">Written Communications</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SolicitingMaterial', window );">Soliciting Material</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementTenderOffer', window );">Pre-commencement Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementIssuerTenderOffer', window );">Pre-commencement Issuer Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common Stock, $0.01 par value<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">FGEN<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 2 such as Street or Suite number</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementIssuerTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 13e<br> -Subsection 4c<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementIssuerTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 14d<br> -Subsection 2b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SolicitingMaterial">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 14a<br> -Subsection 12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SolicitingMaterial</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_WrittenCommunications">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 425<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_WrittenCommunications</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>8
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>9
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
.report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

.report table.authRefData a {
	display: block;
	font-weight: bold;
}

.report table.authRefData p {
	margin-top: 0px;
}

.report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

.report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

.report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

.report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
.pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
.report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

.report hr {
	border: 1px solid #acf;
}

/* Top labels */
.report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

.report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

.report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

.report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

.report td.pl div.a {
	width: 200px;
}

.report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
.report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
.report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
.report .re, .report .reu {
	background-color: #def;
}

.report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
.report .ro, .report .rou {
	background-color: white;
}

.report .rou td {
	border-bottom: 1px solid black;
}

.report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
.report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
.report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

.report .nump {
	padding-left: 2em;
}

.report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
.report .text {
	text-align: left;
	white-space: normal;
}

.report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

.report .text .more {
	display: none;
}

.report .text .note {
	font-style: italic;
	font-weight: bold;
}

.report .text .small {
	width: 10em;
}

.report sup {
	font-style: italic;
}

.report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>11
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.25.1</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>1</ContextCount>
  <ElementCount>23</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>0</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>0</UnitCount>
  <MyReports>
    <Report instance="fgen-20250604.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>100000 - Document - Document And Entity Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.fibrogen.com/20250604/taxonomy/role/DocumentDocumentAndEntityInformation</Role>
      <ShortName>Document And Entity Information</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="8-K" isOnlyDei="true" isUsgaap="true" original="fgen-20250604.htm">fgen-20250604.htm</File>
    <File>fgen-20250604.xsd</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy items="23">http://xbrl.sec.gov/dei/2025</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>false</HasPresentationLinkbase>
  <HasCalculationLinkbase>false</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>13
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "version": "2.2",
 "instance": {
  "fgen-20250604.htm": {
   "nsprefix": "fgen",
   "nsuri": "http://www.fibrogen.com/20250604",
   "dts": {
    "inline": {
     "local": [
      "fgen-20250604.htm"
     ]
    },
    "schema": {
     "local": [
      "fgen-20250604.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://www.xbrl.org/dtr/type/2024-01-31/types.xsd",
      "https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd",
      "https://xbrl.fasb.org/srt/2025/elts/srt-roles-2025.xsd",
      "https://xbrl.fasb.org/srt/2025/elts/srt-types-2025.xsd",
      "https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd",
      "https://xbrl.fasb.org/us-gaap/2025/elts/us-roles-2025.xsd",
      "https://xbrl.fasb.org/us-gaap/2025/elts/us-types-2025.xsd",
      "https://xbrl.sec.gov/country/2025/country-2025.xsd",
      "https://xbrl.sec.gov/dei/2025/dei-2025.xsd",
      "https://xbrl.sec.gov/stpr/2025/stpr-2025.xsd"
     ]
    }
   },
   "keyStandard": 23,
   "keyCustom": 0,
   "axisStandard": 0,
   "axisCustom": 0,
   "memberStandard": 0,
   "memberCustom": 0,
   "hidden": {
    "total": 2,
    "http://xbrl.sec.gov/dei/2025": 2
   },
   "contextCount": 1,
   "entityCount": 1,
   "segmentCount": 0,
   "elementCount": 24,
   "unitCount": 0,
   "baseTaxonomies": {
    "http://xbrl.sec.gov/dei/2025": 23
   },
   "report": {
    "R1": {
     "role": "http://www.fibrogen.com/20250604/taxonomy/role/DocumentDocumentAndEntityInformation",
     "longName": "100000 - Document - Document And Entity Information",
     "shortName": "Document And Entity Information",
     "isDefault": "true",
     "groupType": "document",
     "subGroupType": "",
     "menuCat": "Cover",
     "order": "1",
     "firstAnchor": {
      "contextRef": "C_635a69f0-1a0c-4eb4-9b96-ad916bfa62eb",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "h2",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "fgen-20250604.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_635a69f0-1a0c-4eb4-9b96-ad916bfa62eb",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "h2",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "fgen-20250604.htm",
      "first": true,
      "unique": true
     }
    }
   },
   "tag": {
    "dei_AmendmentFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "AmendmentFlag",
     "presentation": [
      "http://www.fibrogen.com/20250604/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amendment Flag",
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission."
       }
      }
     },
     "auth_ref": []
    },
    "dei_CityAreaCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "CityAreaCode",
     "presentation": [
      "http://www.fibrogen.com/20250604/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "City Area Code",
        "documentation": "Area code of city"
       }
      }
     },
     "auth_ref": []
    },
    "dei_CoverAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "CoverAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Cover [Abstract]",
        "documentation": "Cover page."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentPeriodEndDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentPeriodEndDate",
     "presentation": [
      "http://www.fibrogen.com/20250604/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Period End Date",
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentType": {
     "xbrltype": "submissionTypeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentType",
     "presentation": [
      "http://www.fibrogen.com/20250604/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Type",
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine1": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressAddressLine1",
     "presentation": [
      "http://www.fibrogen.com/20250604/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line One",
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine2": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressAddressLine2",
     "presentation": [
      "http://www.fibrogen.com/20250604/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line Two",
        "documentation": "Address Line 2 such as Street or Suite number"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressCityOrTown": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressCityOrTown",
     "presentation": [
      "http://www.fibrogen.com/20250604/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, City or Town",
        "documentation": "Name of the City or Town"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressPostalZipCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressPostalZipCode",
     "presentation": [
      "http://www.fibrogen.com/20250604/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Postal Zip Code",
        "documentation": "Code for the postal or zip code"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressStateOrProvince": {
     "xbrltype": "stateOrProvinceItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressStateOrProvince",
     "presentation": [
      "http://www.fibrogen.com/20250604/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, State or Province",
        "documentation": "Name of the state or province."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityCentralIndexKey": {
     "xbrltype": "centralIndexKeyItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityCentralIndexKey",
     "presentation": [
      "http://www.fibrogen.com/20250604/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Central Index Key",
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_EntityEmergingGrowthCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityEmergingGrowthCompany",
     "presentation": [
      "http://www.fibrogen.com/20250604/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Emerging Growth Company",
        "documentation": "Indicate if registrant meets the emerging growth company criteria."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_EntityFileNumber": {
     "xbrltype": "fileNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityFileNumber",
     "presentation": [
      "http://www.fibrogen.com/20250604/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity File Number",
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityIncorporationStateCountryCode": {
     "xbrltype": "edgarStateCountryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityIncorporationStateCountryCode",
     "presentation": [
      "http://www.fibrogen.com/20250604/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Incorporation, State or Country Code",
        "documentation": "Two-character EDGAR code representing the state or country of incorporation."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityRegistrantName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityRegistrantName",
     "presentation": [
      "http://www.fibrogen.com/20250604/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Registrant Name",
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_EntityTaxIdentificationNumber": {
     "xbrltype": "employerIdItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityTaxIdentificationNumber",
     "presentation": [
      "http://www.fibrogen.com/20250604/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Tax Identification Number",
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_LocalPhoneNumber": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "LocalPhoneNumber",
     "presentation": [
      "http://www.fibrogen.com/20250604/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Local Phone Number",
        "documentation": "Local phone number for entity."
       }
      }
     },
     "auth_ref": []
    },
    "dei_PreCommencementIssuerTenderOffer": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "PreCommencementIssuerTenderOffer",
     "presentation": [
      "http://www.fibrogen.com/20250604/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pre-commencement Issuer Tender Offer",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r3"
     ]
    },
    "dei_PreCommencementTenderOffer": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "PreCommencementTenderOffer",
     "presentation": [
      "http://www.fibrogen.com/20250604/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pre-commencement Tender Offer",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r5"
     ]
    },
    "dei_Security12bTitle": {
     "xbrltype": "securityTitleItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "Security12bTitle",
     "presentation": [
      "http://www.fibrogen.com/20250604/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title of 12(b) Security",
        "documentation": "Title of a 12(b) registered security."
       }
      }
     },
     "auth_ref": [
      "r0"
     ]
    },
    "dei_SecurityExchangeName": {
     "xbrltype": "edgarExchangeCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "SecurityExchangeName",
     "presentation": [
      "http://www.fibrogen.com/20250604/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Security Exchange Name",
        "documentation": "Name of the Exchange on which a security is registered."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_SolicitingMaterial": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "SolicitingMaterial",
     "presentation": [
      "http://www.fibrogen.com/20250604/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Soliciting Material",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r4"
     ]
    },
    "dei_TradingSymbol": {
     "xbrltype": "tradingSymbolItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "TradingSymbol",
     "presentation": [
      "http://www.fibrogen.com/20250604/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Symbol",
        "documentation": "Trading symbol of an instrument as listed on an exchange."
       }
      }
     },
     "auth_ref": []
    },
    "dei_WrittenCommunications": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "WrittenCommunications",
     "presentation": [
      "http://www.fibrogen.com/20250604/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Written Communications",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act."
       }
      }
     },
     "auth_ref": [
      "r6"
     ]
    }
   }
  }
 },
 "std_ref": {
  "r0": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b"
  },
  "r1": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r2": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r3": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "13e",
   "Subsection": "4c"
  },
  "r4": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "14a",
   "Subsection": "12"
  },
  "r5": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "14d",
   "Subsection": "2b"
  },
  "r6": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "425"
  }
 }
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>14
<FILENAME>0000950170-25-083676-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0000950170-25-083676-xbrl.zip
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M?T>P%O2=)#R.^82<1 E+_(C%I%?UVH!A^DUR&,?D'*OEY)SG/+OD05,V.B@
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M2RXA_L(SS_86NS"7MSBJRGEI!L.D13IJ:TW-'!4D2,=>S,E/BOAW$$+3@D\
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M(ZJBD)\L17')'8M3?KR-O4Z)6'M]1/RR6.TSLM8E&TG/3<^J:7I:Z'/J,=W
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MZE99L4Q[14DW,WD#$5;&A+>LW/YWQ1CTFCE:2\RJFIBNV;07(5JC!+T:,JH
MK(E*5Q(.DZ]IUF>XC<62F$_(A5!Y !/^B2<8">LW%F?FSFN.7^2[:3?(\?^(
M8@!DOP"!<)&A2G J)"^T=9CGJ1^))VE/!U"P-+P!TV HM3RL+TNZ.YRO<-BO
M35%&E"^"&2::%5*##<:@PLE<*FAD.!ZB;R>6FY4^ RGEL5BXSLN(-Z$]>UQF
ML(G,,L%)JKU$L=^4UQ*_JM=E7,?O0#]XB0MZ$_+*)37=<$0=^J^:#4.)XS(Z
M\*^:UC2K%V]8U;P0&8 9[Z>(RC*Y;U3?_KBQQB4)+<'_RI80X8^\D$YP>#=;
M>5@MM!J@+"QY,<&%RG@(1(V84-'F.(X) NRV$: 3JO)X+#BA />X3'6?\T:M
MXJ.H!AM-XTC+]F#,]6&^Z),YGL&QLD$1ZZ*(/9F>:-"K7(M5GJC AR?=/MYF
M2K\OKKR:><_^[0?O\$^%":\EV555F^ZF#OYV[*:B/5O.ZUU7H+_P<^A>60S^
M;C7N6HT=Z':@>]T\ *3%C061[U98$UEPA5LQ;P3\:MN]> \[6+NR:$[3Y3&L
MS[4(MQT?_TJ7@=R3(>U(8'VP/YHY*%X#:WMIB[;2&J'#9>,4LBV0?)94F:>!
M7FVFXOU3@[/F-V!DD.'QIV&?)Y1?J\J_U>:@&-Z.M6'XB+">5:\.N^$'7>8#
M]<K8VF$*K^</=6N0TU\N_DE.6)1=1@ 1/!T/*W_YTBD_=;NW?/W:PXHP>BQR
MW.O<4FS9CD#CEBV!^G9'?<-EBGSL"7G$/7(;=QS[E?.9'?1>*)?>#$1W*MWS
MJW08Y[L=Z+YC%B^462RH=*[[_"K=F0B-/Y>A\95")%0A=SM5H1W7VP+OZ0Z,
M+Q.,6Z(H[?S[;P+I5<78#K1_Z8#<$N[QTL'8$>D"9ZS/21?#:)E,'#IB!2,G
M4<S)/F9Q!$&9:5F&579%T#GYUZ?S+R1(_3%ZN-ZM\0"5UW)6_BZA8.L2"NZ#
M6FY3-^</?EGSO<GK1L!>]_/IX<7OY\>])PSJNPF5;3J_X:QV(Y5,7IR=G+KB
M;7R-93=M!>-X0GPVSD72782)DR)46(:G8PZE/" 0XY@]/F!Q6(6;"T.T+(!1
M\'R,>0JB/2"P09H!!.9.7;D9=+BV&,-'1A1:#X@,-.Z^"F-)I8?4N7MT+_60
MQ#?DX-H!;0>T5PLTHZG?*]%"EG_6R)KYK>IGVI[=X??+P.\=T'9 VP'M%9S*
M_602;;/>K2.P>=HO )NW&XK+MCZWQZ^[6ZX%"'Z:M%_5*BT&N6O3(/=7NH"M
MO$5^30<).8P#O@WQ[#OYOE.*=D#; :T&M*9]+P:ZWCV#U;26&0?ULM;'SSSA
M&8M)1QZ:MMNK?'-[E>];7AI,/O[E?6M0#../_P]02P,$%     @ &H#)6E(D
M9^:#"   '6$  !$   !F9V5N+3(P,C4P-C T+GAS9.U<;V_:.!Q^OT_AR]YL
MNH4$NN[6:G3BVO6$KFNKTNFF.YVFD!BP%FS.25KZ[<]VXOS#"12:!!#3M++D
MY\?/$__LV$]M/GV>3UWP *F'".YJ[9:I 8AMXB \[FK?!GIO<-[O:Y_/7GWZ
M1=?!Q67_&ES#1]"S??0 +Y!GN\0+* 1O!E_?@N^_WUV!@3V!4PM<$#N80NP#
M'4Q\?W9J&(^/CRUGA+!'W,!GU7DMFTP-H.L1^#F%%K\.+BP?@M..V3G6S0^Z
M>7+?/CX]9G_-UM&Q^?%7TSPUS50Q,GNB:#SQP1O[+>"E6-T80]>%3^ 280O;
MR'+!0-;Z#O2QW0(]UP5WO)@'[J 'Z0-T6B'HW'-.O5"$;]$Q]*^M*?1FE@V[
M6DK*" TI&4,L5/!JS0_F>PU8OD_1,/#A):'3"SBR M?O:@'^+[!<-$+080_8
MA?S)9 )2MUF+8.\4XF#:B2N<#ZG;(G3,*S(-./<A]M#0A3H/@U0\-T_O\.8+
MBX\8LU7HAM%,<B;X\2BJS&P;W[]>A4TJ@UV$?V:B4^3,(X/?'EH>E.&!IX\M
M:Q:7&%G>4$1'-P09&>Q E-7L0;LU)@\&NY$)Y#<=7_5\S&,CO)D.126$64;Z
M+$EBPO,%@='C:)^<G!CBKG;V"@"1*&@Z(]0'8;Y<$5NT1$EE_'^ZK%'GE_1V
M1S]JMQB8!K RTPKH&IN1D.VT%HFXD=<E(1N)UWY<5*^R55>JT9.EE=EF0-?W
MY!6=7REBH$[6YU'(IS#_4%JI.O&32BV,B2]JXI?DQ=D,X1$)K[!KO(5.*7'A
M_=,, O[AVUU_^8A@^-:<8#)],G@10X[B\F</.U^PC_RG/JN+3@4)#2 V>MRQ
M\!\KA4N*DJ0#V4L!"3EMD_]AKXS4VR/^R,! B 92<)^,/$@./O"@<X//Q.<9
M94,]#I_=%;L0%8Y"2@K:EFL'[O/+);0*BT4795-E&U#V,_&(W6C@R;?P'1Q5
MW,!BT#N=4#CJ:OS-HDLTGL*O5V_Z",AG.KN:QSJ/&XT@&<W6$+K\<471G&?)
M4"1DB$%9HB.?%XAALK6*=Z?#WK-)M7'%Q,Z$NKP_$YJ5OWK7?LW^\^.<L,E5
M;^CYU+)]B22H=;7%^T8]I'JL@1PQ!7&ML8)4]GY-I,Y9KO38%/"<.%#UH-*W
M:Z(D<_D64D18.CM\9JK@IHZKF20?/$JXB=LU40H[?L]QV'#K13]83X1M!;_B
MV(;)=IY!MM,(6=XE;N@]><3+J*8BFR!Z2]B4U?T;S0KZ=DEP$W0';(( ;^@M
M)0\H7!>4$LZ'UTKYG'5M:KE]]DJ;_PF?"KGFXVHE^84M4<<(C_^@Y-&?G)/I
MS,+%5-71M1*^1"Z\#J9#2 M9ID)JI=;'-J%LT2$F5"+USDG VO:IM&^5EZI5
MP!T<(S[=P<)7*62<"ZN5XKTU[SNLPZ 1"E=T2W*A*+XFTGS=Z=Y.""[.V860
MFJC=4I9H4S;_L(7EU?>\ -)[/@&G-Z.1DNK2(LU0?Q;I!N@.H!U0EHOMSO">
M+X 4)!=":J;V96Y/+#R&!?U>&5871>(BFZW3\?@K&QLILEP5P<6@FNC=4XL[
M\H.GZ9"HF&7OUT3J+]98;"W-\S[ T<#G*<BIXU0D>1ENPK)/_-</$.O?!MG5
M.YMOD8 JYV29E?0/=Q@_IY7\ XZCG0D,\(]$^3?R9L3=E^:;662OR3?& !RD
M2K;IY?>Z#Y<[=QP#<) JR2K7XVNRCNW'$ PP-/$+JCKX\S7[IK0Y1I5<"]?O
M:Q*/'-X(Z9W\ #@FN,&-:.E4H>7^D=2F)5G_OY 2T9<)!1RR-A499^"%A(28
M@(%6/BJ5F08OI$:@\G:1N-7KR1D+FPF)P(!  PRN>OY*MV$S%1(2A)@@ JU>
M2^));": XX 0J'K2I=;$9CHRT*G>$5504X_/.AF;*4JP  >KGGR!M;&9"@8*
MLJ@U9%O> EE3@H ! J<&TLO,D#5%,%C=3N&"$!B$R$! URBK D%U*<E[*FOR
M%V4!&8%VY\WP+9"H=3!/VRUKLI=00&)5/C@M6C'K4H^!@$2JDG?&J%DW5T(,
M$()4R5;IW*S).L("6; 5V/=HUKJRJ"VK9Q^7,(@B#)NP@6'FZR&9J/B(DJEJ
M%X:LCA092T7>51U4E7LW)-5%3ZE)JJH='?%#S?M)31(MW><A&1>;2MM /;W[
M(\\XMI&:)+IT3XAD76XH;:.$SJH2.MLE87'_B%) SCS:&OK*725*!8O&T=:(
M*-AKHI2A\HR:%U*P R6K0.42-4^]=%]*5D"Q3=2\C,7=*EGN.5NH><(K[6')
M:ECN$C4O2[VS):M#808U3WS)?I>L@C)'J$DI1;M@)'NE_],DX57WQD@!*WE!
M6R1H=2G;)*)H'XVDKC1\MH&P:G=-GO2"U],H\<(]-S%MM<O3)&GE3AS)=]'=
M:9)JZ?X<2;G8XDF?RTFY-&P=\S-_8B=_K*K('7KI TG129]\]5E_ZW#@YW#@
MYW#@IUI*AP,_M9 ]'/@Y'/@Y'/BI@O#AP,_AP,_AP,_AP,_AP,_AP$_9+I/#
M@9^7//"37KB_B",RLRC#T^T)<IUG[O+(+9$)9?VYJ[5-LVWR;]6:L84>S]6N
MQI8)@<?(D!FGK4Z);1*676;'NMI'.ZZK8*V>-%QG3P2&Z_Q$E[GCNDK,@D3D
MR9Z*[&1$MO=(9-J<2$:9O4K6G*V1J-SUH:;<#4ET[OJ[L,!"27KD^[T06&"_
M)#*/]T)FVK1)M'W8"VU+7)]$[F][(3?O$27Z=GV:NL1@2H1^W'&ABZ94\M[8
M]6%UN:N5:-WUF6N9#9:HW/5L773/8FV=79_EJ.VW6-_1KO=&E7>79.:NOQ!S
MUE^2EKN^R"BP#Y.6>\[,+=J2E-_ZD_M29?X/__KD\/(G(_=%V=&%U-=IAU?"
MK_,^^Q]02P,$%     @ &H#)6F]X D'_$   H.P   \   !F9V5N+65X,3!?
M,2YH=&WM77MSVD@2_W\_Q5SVLI5< <9X_0@XJ<(8V^S9X .RN:VMJZM!&F#6
M>ITTLDT^_77/2$)@X9 8;&$F54F,T+SZW;_I&1^/A6U]^HD<CQDUX7]R++BP
MV*?FOXN[Y=+N\8[Z""_L1&\<#UQS0@(QL=C'-QXU3>Z,JD?>?<VF_H@[51H*
M]V_<]EQ?4$?4OA:Y8[+[:KE6O&.#&RZ*@MV+8L"_LB(U_PH#4=TME]_6/#?@
M@KM.U6<6%?R6U=[(Z9C\=FZPHG"]:KFTSYVD\TK-YDYQS/AH#-W!%P][&[CW
M."A.=N#Z)O.+\ 3&./;B[H>NH^8%$_)$M!PU6$U^-Z0VMR;5/K=90-KLCG1=
MFSKQBP-7"->&=^7ZJ,5',#I." ?!]O$X=V,N6#'PJ,&JGL^*=S[U:JG!*S#X
M8^/)[VZ8[^!:'-=A<O%WW!3CZA#H:\#WS,%A?_EY]Z!<.][!%I^.=SSX"^1,
MR&I8- @^OK$I-(\:R?_A,_/?Q-.-:;R?R:)5DZ_R*[1-41 %A \G\S0T7,OU
MJS^7Y9_:8HK>*9$8N)99FYO@:DC\YS_^0SZ2!O.1:@2>#[D)WW!J$>X,7=^F
M2#$2D]6$IT2,>4!,UPAM>+- @  W\,5@0@8^-6Z8" ID3 ,R8,PAKLV%P&^9
M0<. $2X(- 9BC<D[_IXXKH#V@ODX('5,> A/[]S0,HG%;Y@U(:J=X=H> UT&
MKD'GODV$"_-0SZDS(7Q(O'!@<0-:F#PP+#=@9BDM.L^N)T_D\>[*>-R\'_,!
M$%X9Q!>DR+<LQ^J6_-!RZ,6N:+$&#,K\'Q!VV8?)#->7-J4:@EGV+3 J)' M
MOB;9[S4;G?8IJ5\UVZ?PMT_Z'7+6:M?;C5;[G-3/N\TF/GY9XN5"5.0LT54Z
MHGI0.C@X?#OO<7Z0 #(@6)U+7#5)^NC-EA03\D[ZOE]^OJ^4=XV$CIN@"'5P
MUB8Z[!^<])K$$0EIUMX7B$DQ3("PP1V2WT*@Q7Z!5,H5^!<(+K5&!A_@]JGM
M.B/@SDFW<]YL%TBKW2@5""6G$-7=41]C M^+:(L,8QO)KQ/7]]T[YN>474A6
MBR$A N)17TS(&#@$W(&W0;U%** WTF7_"SDR[C)Z59).-C[C#G4,?*D^\AE#
MR=Q<9D7+RRFO,*[^PBUX<R1 )?H^&. ":4OZ0-A=#P+7X/)3 160FO F#X0O
M<R1"1\@:2 4DVV)&OH,\( B-,83GL!@N)DHD-I%Y]5%>K>(Z\Y=YK[Q985VW
MV6CUZY<]'<G,1#*,Q&Y#J>-Y2'T*/C,QTD)9Z5G[/?1=R*=A6)E4X_]S+Z,!
MP0924PBZ6'R!PS1E%DX%,2( (<.JS[KVNN=SBU0^2.>^1]ZAO<'(1 $(RC'X
M@2!)N()#9/F*=*=7=$*.5+@@YXI/<?)W/&!Q]P7BLT!@HP(8+L^S9#?0!1BV
MZ<NV:_(AAZ<9-/$YVD %.^#HTN.YP\TU?!EDS:,9K*&/X0)4[BLP!HR4#7%$
M #\B_4'FD..((YEL*!&J8$PMBXPI^"[DC,THC@5R%A@^'V 7DH>V@K*R(Q%W
M<9"2DEB< $CMQH8M]6@=&R(([U5X KK+#3JPV/L229L\"3KZ$'&"GB.7T2Y%
M%BNR7P_"49O>L,1V&6/JC&*;ELG[$I$#?J-3*7D4VTA1DU%2-*T ;<_@+V:(
M>!0ESM@7K->4\'1  B8#+C&.1#P[#MA6-U<W0$MP(\6"H%.!U@$'RJN$#]P!
MTA6F8(-!#Q(VV:$($6..>1FD,&U%967(8\\6I3.1BLMF*'U#U[+<NZ"J.3(+
MLO5;G3;9!06!/QMG I4\9 <:>3*$0-[F< C60^9E02SK/8:V(Q4R35\ZQ3@%
M@ZS8.0X8B&^4OV=Y-QXD(A\Y!RWTV<QX1]]+:>\AJ<'P')2.8H8L25C@V30F
M!4/&A42ZP)E@.IU!]SPLFWQ3"';W2GM[>ULB!6GN;YKMN^(.MT.;_ L<H\IZ
M&C08YTG8HH#KTJ4.N8X<LPKO,>#W(';B0FH<'8&BC=#84=L-,8 ?SBT+%>R4
MR1( @A%$B"8?PGQ@8.ASV7/RV'(-F5U&"<)GA^.G'FIJ$-E=1B&J:TE8&K+5
M:SJ12AZ9VR$\)B-^BQ; \UTB]]$)DU8Y#OQXW-:+VIHADR8!/F-P2]P(8,-4
M\SVV&F#&'@08V#KD[Y5*8;]<+@ _='0X8Y8'RBR?N:X (6&D@K2K.PZ[)W7\
M,=X-/]E>:QTQU&+#[9*-.8NPA)KC\^?5<C1L6M._)^NH;%[6T9CF^M<^,YB9
MOT1#;HM/4PKE=0= )YM%,H[Y1>B! $L\1($T'VH(P1B,>](%4TBRO8E2I)GN
MS-":$'8/OE=,D=]9[/H;*,N[!(9%;QQ/R &UV5Q ]AN)7)XD)'N/:J8\<Z[^
MLE(;6NR^: (79<A<A:F'ME,S>>!9=%+%;VMQB6Q<.R.K9.=J8R,S%$]&-BP"
MQ?)2-(MN-4\UL\^]UN\325W*^OVEK(F:C?VYD(X[:*.*$*;Z0E:RUV:_ #51
MCSTZ8L6!S^A-408R56K=T4GP&HK6\Z9_:ZQ9W_;0;V_S0K\N&T)&X!AR8QG-
MA/+QF @LW'&,8J .;E,K,.0T,EFY*CDJ/64R:Z^")]]&+K=)A6+X^K,72=Y,
M#/TP9"\HR,M/Q/>1W7.0[#C\5ITDM2!QV)A\CRB+U+OLK]QA]G/N)(]='YRL
M;\HIHY\EZNR6FJF/$UN\H:M*6[(7YF9HV^S*LKM\,%_QR!K%HD6*E:Y296]8
M"2$7/&"0F?EI0R03KL75 !IXR((8F_<&\V1!2. Q@P^Y 52>S%2'Q+O*B\PZ
MLB53T+#("E]0G,.QN1.R" 8&"1V&\!B"6D.]%J%.LDN?Q=@E%L? :S[#^4&G
MZ.<D_!75&PRY;R\Z);6US#44<W'?00$4LB[69!:81G^2HO9"4YG:HG ]K$N0
MF[64W%'L0N(B$.;+0T,%XLG2%5!O'Z3"G,2@HT(_YHIN'Z^>AI>QWRQQ*DS+
MLMF#B7B^>\N#5.W$=W<.7P;,OY7B&4LB+/]VIB*C RG-2#X)GA0HZ+C@64+K
M7S<OM&[&ZHJ&KX%;><S'<IZ@)C'\D9I+GF3O(<YJTPE:^ 0:E?6-$^*$]D!I
MK)%:EW+FB!(,I2\7\]5+6*3/X!F:H'3#*)B#[F"M\,/=F,&;[G18[#@R>4E%
M)4S+1&M@1EX(;( +1HP[$=XA?5G<HZ WT*5P1TQ:C,2-Q49H$&+*PY+<)@"O
M.2W. KJ<Q@976JGIS%++4 AS $I$12B+DD=1,#-#4F:!0?)=)W+/R6)8NI3&
M3 \'7'!"^?*B86>'>,#&PG3E=UR,%\:36)0,$A:HV!(]CMQ0G!(B-IZST'CL
M#V;KLN5(D:^/8[JXVM"F G>KXHKEJ"&.!'\=%WV +)<K*!\#W,.2V=3TE.&6
M82CUL:8<I2S"[1-?A9*JYD9BN.+1B4@7R>YQB  YDY0]2G>(@:T2MJC0%YX^
M$IOK,&;U9OQ!9OXB=OV\\WNSV\:#F)?U+[G&&- 07+1ZJ7.D]?8I/&J2;NO\
MHM^3'SLGEZWS.G*G1SIG\MOK>K??:O;(Y_9ILSO?1>^B?GE)3II$T:%Y2D[^
M*,B>DF\:T%>_^QF^PL?-]EFGVX /K3:I-QJ=[FF]W6B2+ZW^14$.!V2,1^[U
MZ_TF?F@WOY _.MU_DOKU]66K43^Y;.(A6.BYWZTW8.I7]=.F6DX'A[QN=F&4
M*S5*9D]:(;,4<G_SXJH+1G$+(%]8X[3P<AQ-+SD/XF.&;%@A)N%X;A%:0:K&
M)=8!3F<*?+B.-4EEV>B-9O*D;&\O^YPF0U[H>V[ M+1G2?O!YDE[RTF?'X<0
M)T'L<R;__9GC(TD6+P&)2#<">>?+(7D7PXKH**+K#7[[W&WU3EN23\ENONP*
MVQQ-VWRIM\#OH&6')G^0?K=5OYPV> 0SF$&B8J).SVW!XT05"T^*4+Z#N++G
MJCQ-9GP'N>T0(^  3Y$ A7BN3&%AFF/(+.HA*AC@GC(BAI,'1XNFASOG4D=U
MXB4^OR3E[&&V.K66B&_% C,3ER<(M@*OHN.9\7&$1S81\$T8;.%YJ93 1V Y
MP1)@>3)(IP9+V.;#S;/-<U5@I!Z*L>OSKSD$=DXFJD(XP:3BW#M&7E":)=$0
MP$@?'XSJCJ.E14?85-E4D,JW10+7I-&:^5@EVMQ+G5=>YZ4"\[??_?"E FMA
MRI^]UGF[WO_<Q83K'-*ML\[E9>?+?UYK!=LWJUK6<<O76CA7?*[P8*G95/(T
M&5)\R5H_7=>HZQI?=5UCN728G\K&;;J.=VW1^7R,\G157R'VT$:4MMWL]<B7
MBV:WV3G+OI0 ;YB02F?.QWMJ:V[V>,7L9I[:M.$^)E!>E)')]Y.(TX3P=,@-
MN<.4G():$$'^A!F$D$>9,@Z7296,] /IAP0 B<;7BQ QN6'TBJ+%?KE4?AN_
M#BRPJ!>P:KR!J5081TN, ^9_ VYQ,:G&K\=OP6MFHB&R]]V#TH?*V[3BQD(:
M:>Z.,!>U/=HKE8^6:@L_^0_F&8=^*"A8Q:4,5%69*7R0+6+II<#ZX%OGXYO*
MFTP+AD8J^BPI#Z0\1*,&/!>X\1D).[S[($)--?4CFZ?:+K!FNROUL82;']^X
M%OLOV/&;2JR'Z8>[2-\5;OHL=S?2S/623QE_.0QGQJIJ87K6@&TI#H$EG+^2
M<U$0NLXU/7$5RT71>@'/N8"UJ'M&U/C MVVZSC\15UWN&MY)-9-7:Z)CDDO$
MX)$G(CSUU5)X)]@AD.*^K$8LX1'3"<G>A](!C+Y6A4G'T8?J1IWT%,KS&<BF
M\+M-;5;5'-\BCO?Q5S ]8'D>E_T,OAU^P/0W?U#MZ@#+;^!$Z]A543"=OAE
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M,0M7,V W@5'M@N=3$*N#UZ4;[SM_(B&^5N"#D_,%D6_N)'"PR[ROQQ ,4CE
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M   1              "  0    !F9V5N+3(P,C4P-C T+FAT;5!+ 0(4 Q0
M   ( !J R5I2)&?F@P@  !UA   1              "  3T<  !F9V5N+3(P
M,C4P-C T+GAS9%!+ 0(4 Q0    ( !J R5IO> )!_Q   *#L   /
M      "  >\D  !F9V5N+65X,3!?,2YH=&U02P$"% ,4    "  :@,E::DQH
MEB$*  #P-0  #P              @ $;-@  9F=E;BUE>#DY7S$N:'1M4$L%
3!@     $  0 ^    &E       $!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>15
<FILENAME>fgen-20250604_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2025"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xlink="http://www.w3.org/1999/xlink">
    <link:schemaRef xlink:href="fgen-20250604.xsd" xlink:type="simple"/>
    <context id="C_635a69f0-1a0c-4eb4-9b96-ad916bfa62eb">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000921299</identifier>
        </entity>
        <period>
            <startDate>2025-06-04</startDate>
            <endDate>2025-06-04</endDate>
        </period>
    </context>
    <dei:EntityCentralIndexKey
      contextRef="C_635a69f0-1a0c-4eb4-9b96-ad916bfa62eb"
      id="F_3b65e9a4-6154-4acb-9acf-0d8df1c457dc">0000921299</dei:EntityCentralIndexKey>
    <dei:AmendmentFlag
      contextRef="C_635a69f0-1a0c-4eb4-9b96-ad916bfa62eb"
      id="F_a1797866-cf90-4367-b394-152099b6f327">false</dei:AmendmentFlag>
    <dei:DocumentType
      contextRef="C_635a69f0-1a0c-4eb4-9b96-ad916bfa62eb"
      id="F_9036f13e-3e42-4021-840c-8b8e1f10e17e">8-K</dei:DocumentType>
    <dei:DocumentPeriodEndDate
      contextRef="C_635a69f0-1a0c-4eb4-9b96-ad916bfa62eb"
      id="F_1af18199-20b5-4f32-9d1c-c504d051d337">2025-06-04</dei:DocumentPeriodEndDate>
    <dei:EntityRegistrantName
      contextRef="C_635a69f0-1a0c-4eb4-9b96-ad916bfa62eb"
      id="F_4b57d9b7-11f0-4dd0-a7e7-cb2045866d9b">FIBROGEN, INC.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode
      contextRef="C_635a69f0-1a0c-4eb4-9b96-ad916bfa62eb"
      id="F_2df28f37-d62d-4885-ae0e-d18999b774c8">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityFileNumber
      contextRef="C_635a69f0-1a0c-4eb4-9b96-ad916bfa62eb"
      id="F_dc797436-a410-454a-9919-8bea6e9d5ec5">001-36740</dei:EntityFileNumber>
    <dei:EntityTaxIdentificationNumber
      contextRef="C_635a69f0-1a0c-4eb4-9b96-ad916bfa62eb"
      id="F_7ed75dc0-d0d2-4784-bd1e-54d2395efa64">77-0357827</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1
      contextRef="C_635a69f0-1a0c-4eb4-9b96-ad916bfa62eb"
      id="F_04e8631c-d569-4c8d-8b28-8316940a1d3a">350 Bay Street</dei:EntityAddressAddressLine1>
    <dei:EntityAddressAddressLine2
      contextRef="C_635a69f0-1a0c-4eb4-9b96-ad916bfa62eb"
      id="F_ee96240a-297a-4a94-a15e-2f9610685039">Suite 100 #6009 </dei:EntityAddressAddressLine2>
    <dei:EntityAddressCityOrTown
      contextRef="C_635a69f0-1a0c-4eb4-9b96-ad916bfa62eb"
      id="F_155b2fce-ba34-4361-9fb6-51edd9222f5e">San Francisco</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince
      contextRef="C_635a69f0-1a0c-4eb4-9b96-ad916bfa62eb"
      id="F_87573e3f-76ab-40bc-9e09-3d64d9827ae6">CA</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode
      contextRef="C_635a69f0-1a0c-4eb4-9b96-ad916bfa62eb"
      id="F_3e731176-9963-4a76-af3c-4b56676fa64e">94133</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode
      contextRef="C_635a69f0-1a0c-4eb4-9b96-ad916bfa62eb"
      id="F_249cb515-c9ff-4245-8c89-5f1e4dc2b3b9">415</dei:CityAreaCode>
    <dei:LocalPhoneNumber
      contextRef="C_635a69f0-1a0c-4eb4-9b96-ad916bfa62eb"
      id="F_9a66f5ec-2417-4470-a3d4-16e86939f4ee">978-1200 </dei:LocalPhoneNumber>
    <dei:WrittenCommunications
      contextRef="C_635a69f0-1a0c-4eb4-9b96-ad916bfa62eb"
      id="F_7f51db64-915f-4368-b917-29581f915908">false</dei:WrittenCommunications>
    <dei:SolicitingMaterial
      contextRef="C_635a69f0-1a0c-4eb4-9b96-ad916bfa62eb"
      id="F_0a3eaa4a-9ab5-4154-be7f-89636a62518d">false</dei:SolicitingMaterial>
    <dei:PreCommencementTenderOffer
      contextRef="C_635a69f0-1a0c-4eb4-9b96-ad916bfa62eb"
      id="F_c1a7a408-88aa-4afe-90bd-c8d31a589474">false</dei:PreCommencementTenderOffer>
    <dei:PreCommencementIssuerTenderOffer
      contextRef="C_635a69f0-1a0c-4eb4-9b96-ad916bfa62eb"
      id="F_6f55c0a7-9215-4088-8aa2-4d16530b2733">false</dei:PreCommencementIssuerTenderOffer>
    <dei:Security12bTitle
      contextRef="C_635a69f0-1a0c-4eb4-9b96-ad916bfa62eb"
      id="F_1017a4ec-7005-4735-addd-4b800191c687">Common Stock, $0.01 par value</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="C_635a69f0-1a0c-4eb4-9b96-ad916bfa62eb"
      id="F_550e9879-b446-44c7-b4eb-1b054ac8091f">FGEN</dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="C_635a69f0-1a0c-4eb4-9b96-ad916bfa62eb"
      id="F_412972de-18ff-46b8-b58d-b2fe532f91d5">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityEmergingGrowthCompany
      contextRef="C_635a69f0-1a0c-4eb4-9b96-ad916bfa62eb"
      id="F_99ea675d-694e-4ff1-b1b9-2ab3863f94a4">false</dei:EntityEmergingGrowthCompany>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
